Skip to content
Parker Institute for Cancer Immunotherapy
Search Close

PICI Network Researchers Featured at #ASCO23

Eight members of the Parker Institute for Cancer Immunotherapy (PICI) Network will be featured at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6 in Chicago.

The eight, who will moderate sessions about, present or discuss some of the latest findings in immuno-oncology, are:

Below are details about their sessions, which will be at McCormick Place. All times are Central Daylight Time. Livestream or on-demand video options also are available as noted.

Programming is subject to change. For the most current information, visit the conference program guide, or download the app. App instructions are available here. Follow the meeting live on Twitter using the hashtag #ASCO23.

Saturday, June 3

Session Title: The Promise of Neoadjuvant Immunotherapy Across Solid Tumors
Session Type: Clinical Science Symposium
Time: 8-9:30 a.m.
Location: Lakeside Center, Hall D1 and Livestream

Discussant: Jedd D. Wolchok, MD, PhD
Presentation: Are We Ready for a Paradigm Shift to Neoadjuvant Immunotherapy in Melanoma?
Time: 8:40-8:50 a.m.

Discussant: Elizabeth A. Mittendorf, MD, PhD
Presentation: I-SPY Biomarkers of Immunotherapy Response: Neoadjuvant Immunotherapy Trials as a Platform for Biomarker Discovery
Time: 9-9:10 a.m.

Session Title: Melanoma/Skin Cancers
Session Type: Poster Session
Time: 1:15-4:15 p.m.
Location: Hall A and On Demand

Presenter: Jedd D. Wolchok, MD, Ph
Presentation: Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in CheckMate 067
Abstract: 9542
Poster Board: 305
Clinical Trial Registration Number: NCT01844505

Session Title: Sarcoma
Session Type: Poster Session
Time: 1:15-4:15 p.m.
Location: Hall A and On Demand

Presenter: Sandra D’Angelo, MD
Presentation: A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma
Abstract: TPS11590
Poster Board: 518b
Clinical Trial Registration Number: NCT04438824

Session Title: Developmental Therapeutics—Immunotherapy
Session Type: Poster Discussion Session
Time: 3-4:30 p.m.
Location: South Building, Room 100bc and On Demand

Presenter: Adil Daud, MD
Presentation: First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors
Abstract: 2525
Poster Board: 367
Clinical Trial Registration Number: NCT04130542

Sunday, June 4

Session Title: ASCO/AACR Joint Session: Targeting the Cell Cycle in Cancer
Session Type: Education Session
Time: 8-9:15 a.m.
Location: South Building, Room S100a and Livestream

Co-Chair and Moderator: Robert H. Vonderheide, MD, DPhil

Session Title: Pediatric Immunotherapy: CARs of the Future
Session Type: Education Session
Time: 4:30-5:45 p.m.
Location: South Building, Room S504 and On Demand

Presenter: Yvonne Y. Chen, PhD
Presentation: Engineering The Next Generation CARs
Time: 4:45-5 p.m.

Monday, June 5

Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Session Type: Poster Session
Time: 8-11 a.m.
Location: Hall A and On Demand

Presenter: Wungki Park, MD
Presentation: Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy
Abstract: 4140
Poster Board: 461
Clinical Trial Registration Number: NCT04666740

Session Title: CAR T-Related Toxicities: Everything Clinicians Need to Know
Session Type: Case-Based Panel
Time: 1:15-2:15 p.m.
Location: Arie Crown Theater and Livestream

Panelist: Bianca D. Santomasso, MD, PhD
Panel: Perspective on Incidence and Management of Neurotoxicity